$Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction$

Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction

Aim: Sacubitril valsartan (SV) has revolutionized disease history in patients with heart failure and reduced ejection fraction (HFrEF). Our study assessed SV impact on clinical and echocardiographic parameters in HFrEF outpatients previously treated with optimized therapy. Methods: Forty-nine HFrEF...

Full description

Bibliographic Details
Main Authors:	Matteo Landolfo, Federica Piani, Daniela Degli Esposti, Eugenio Cosentino, Stefano Bacchelli, Ada Dormi, Claudio Borghi
Format:	Article
Language:	English
Published:	Elsevier 2020-12-01
Series:	International Journal of Cardiology: Heart & Vasculature
Subjects:	Sacubitril valsartan Entresto Reverse remodelling Sex differences Heart failure Echocardiography
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352906720303547

Similar Items

Left ventricular output indices and sacubitril/valsartan titration: role of stroke volume index
by: Paolo Tolomeo, et al.
Published: (2022-06-01)

A Rare Adverse Event of Rhabdomyolysis Caused by Sacubitril/Valsartan
by: Prashanth Rawla, et al.
Published: (2019-05-01)

Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril‐Valsartan: A Multicenter Echocardiographic Registry
by: Giulia Elena Mandoli, et al.
Published: (2023-04-01)

Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives
by: Yandrapalli S, et al.
Published: (2017-10-01)

Short-Term Effects of Sacubitril/valsartan on Echocardiographic Parameters in Dogs With Symptomatic Myxomatous Mitral Valve Disease
by: Nakkawee Saengklub, et al.
Published: (2021-07-01)

Effects of Sacubitril-Valsartan on Clinical, Echocardiographic, and Polygraphic Parameters in Patients Affected by Heart Failure With Reduced Ejection Fraction and Sleep Apnea
by: Corrado Pelaia, et al.
Published: (2022-04-01)

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
by: Ying‐Hsiang Lee, et al.
Published: (2021-04-01)

Unlocking the potential of sacubitril/valsartan therapy in improving ECG and echocardiographic parameters in heart failure patients with reduced ejection fraction (HErEF)
by: Lamyaa Elsayed Allam, et al.
Published: (2024-03-01)

Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real‐world study
by: Chen Wang, et al.
Published: (2023-06-01)

Importance of the ‘area under the curve’ from serial NT‐proBNP measurements during treatment with sacubitril/valsartan
by: Reza Mohebi, et al.
Published: (2023-10-01)

Effects and clinical implications of sacubitril/valsartan on left ventricular reverse remodeling in patients affected by chronic heart failure: A 24-month follow-up
by: Carla Paolini, et al.
Published: (2021-08-01)

The Efficacy and Safety of Sacubitril/Valsartan Compared to Valsartan in Patients with Heart Failure and Mildly Reduced and Preserved Ejection Fractions: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Sharath Kommu, et al.
Published: (2024-03-01)

Cardiac and Vascular Remodeling After 6 Months of Therapy With Sacubitril/Valsartan: Mechanistic Insights From Advanced Echocardiographic Analysis
by: Sara Monosilio, et al.
Published: (2022-05-01)

Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report
by: Marcely Gimenes Bonatto, et al.
Published: (2020-06-01)

Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
by: David Carballo, et al.
Published: (2020-06-01)

What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies
by: Hisham A. Badreldin, et al.
Published: (2022-02-01)

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
by: Mi‐Gil Moon, et al.
Published: (2021-06-01)

Evidence of superiority of sacubitril/valsartan versus angiotensin-converting enzyme inhibitors or angiotensin ii receptor blockers in the heart failure with reduced ejection fraction patient's journey
by: Mauro Gori, et al.
Published: (2021-01-01)

Sacubitril/valsartan decreases mortality in the rat model of the isoprenaline‐induced takotsubo‐like syndrome
by: Anwar Ali, et al.
Published: (2021-10-01)

Cooling down with Entresto. Can sacubitril/valsartan combination enhance browning more than coldness?
by: Marina Nikolic, et al.
Published: (2022-11-01)

Sacubitril/valsartan in patients listed for heart transplantation: effect on physical frailty
by: Francesco Cacciatore, et al.
Published: (2020-04-01)

Sacubitril/Valsartan Ameliorates Crizotinib-Induced Cardiotoxicity in Mice
by: Lijun Cheng, et al.
Published: (2023-07-01)

Effects and clinical outcomes of early initiation of sacubitril/valsartan in patients with chronic heart failure with a low ejection fraction
by: Z. D. Kobalava, et al.
Published: (2020-12-01)

A Simple Score to Identify Super-Responders to Sacubitril/Valsartan in Ambulatory Patients With Heart Failure
by: Carles Moliner-Abós, et al.
Published: (2021-02-01)

Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry
by: Aldo P. Maggioni, et al.
Published: (2022-12-01)

Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction
by: Ruoyu Jia, et al.
Published: (2022-11-01)

Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
by: Senthil Selvaraj, et al.
Published: (2021-09-01)

The effects of sacubitril/valsartan and ramipril on the male fertility in hypertensive rats
by: Duygun Altıntaş Aykan, et al.
Published: (2020-10-01)

Sacubitril/Valsartan and Ivabradine Attenuate Left Ventricular Remodelling and Dysfunction in Spontaneously Hypertensive Rats: Different Interactions with the Renin–Angiotensin–Aldosterone System
by: Fedor Simko, et al.
Published: (2022-07-01)

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction
by: Stephen J. Greene, et al.
Published: (2021-08-01)

Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients
by: Liu Yang, et al.
Published: (2022-08-01)

Impact of Sacubitril/Valsartan on Circulating microRNA in Patients with Heart Failure
by: Maura Brioschi, et al.
Published: (2023-03-01)

Sacubitril/Valsartan for Heart Failure: Exciting Times but Are Doctors Informed and Ready?
by: Prithwish Banerjee
Published: (2017-01-01)

Implementation of sacubitril/valsartan in Sweden: clinical characteristics, titration patterns, and determinants
by: Michael Fu, et al.
Published: (2020-12-01)

Renin profiling predicts neurohormonal response to sacubitril/valsartan
by: Giuseppe Vergaro, et al.
Published: (2021-02-01)

Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction
by: Juan Jiang, et al.
Published: (2023-03-01)

Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy
by: Vanesa Gregorietti, et al.
Published: (2020-11-01)

Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure
by: Reza Mohebi, et al.
Published: (2023-04-01)

Beneficial Effect of Left Ventricular Remodeling after Early Change of Sacubitril/Valsartan in Patients with Nonischemic Dilated Cardiomyopathy
by: Hyue-Mee Kim, et al.
Published: (2021-04-01)

Effect of Emergency Percutaneous Coronary Intervention Combined with Sacubitril and Valsartan on the Cardiac Prognosis in Patients with Acute Myocardial Infarction
by: Fan H, et al.
Published: (2023-02-01)